T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

Stock Information for Minim Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Minim Inc

T2 Biosystems to Host Business Update Call on October 10, 2024
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.